About this trial
Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Postmenopausal women;
Diagnosed coronary artery disease;
Stable coronary disease;
Disqualifiers
Hypo- or hyperthyroidism,
Rheumatic disease,
Use of alcohol,
hepatic failure,
Trial design
Parallel
Treatments tested in this trial
Trans-resveratrol, 1000 mg daily for 90 days
Dietary supplementTrans-resveratrol, 1000 mg daily for 90 days
Placebo
Other interventionStarch, 1000 mg daily for 90 days
Treatment groups
Trial outcomes
Primary outcomes
1. Sirtuin-1 and sirtuin-3
Serum concentrations and gene expression
Estradiol
Serum concentrations
Estrone
Serum concentrations
SHBG
Serum concentrations
Secondary outcomes
Estrogen receptor alpha
Gene expression
Cardiometabolic risk factors
Lipid and glucometabolic profiles
BMI
kg/m²
Sponsors and contacts
Click on the lead sponsor to view all of their trials.